CN113304173A - 一种改善肝功能障碍的干细胞制剂 - Google Patents
一种改善肝功能障碍的干细胞制剂 Download PDFInfo
- Publication number
- CN113304173A CN113304173A CN202110510202.0A CN202110510202A CN113304173A CN 113304173 A CN113304173 A CN 113304173A CN 202110510202 A CN202110510202 A CN 202110510202A CN 113304173 A CN113304173 A CN 113304173A
- Authority
- CN
- China
- Prior art keywords
- extract
- root
- stem cell
- radix paeoniae
- peony
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 208000019423 liver disease Diseases 0.000 title claims abstract description 26
- 230000005976 liver dysfunction Effects 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 79
- 241000736199 Paeonia Species 0.000 claims abstract description 38
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 38
- 210000001808 exosome Anatomy 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 210000003954 umbilical cord Anatomy 0.000 claims abstract description 23
- 239000002024 ethyl acetate extract Substances 0.000 claims abstract description 21
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 10
- 238000002604 ultrasonography Methods 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 208000027700 hepatic dysfunction Diseases 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 206010067125 Liver injury Diseases 0.000 abstract description 13
- 230000006872 improvement Effects 0.000 abstract description 8
- 231100000753 hepatic injury Toxicity 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 description 17
- 208000019425 cirrhosis of liver Diseases 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 229940118019 malondialdehyde Drugs 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- -1 flavone compound Chemical class 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000007788 Acute Liver Failure Diseases 0.000 description 4
- 206010000804 Acute hepatic failure Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 231100000836 acute liver failure Toxicity 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000010334 End Stage Liver Disease Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 208000011444 chronic liver failure Diseases 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000013252 liver disease animal model Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种改善肝功能障碍的干细胞制剂,由脐带间充质干细胞外泌体、芍药提取物以及药学上可接受的辅料组成,其中,所述芍药提取物包括根部水提物、根部醇提物和根部乙酸乙酯提取物,且3者的重量份数比为(3‑5):(1‑2):(1‑2)。本发明所述的改善肝功能障碍的干细胞制剂采用特定浓度范围的干细胞外泌体和芍药提取物配合使用,在对肝损伤动物模型的治疗中表现出了更好的改善效果。
Description
技术领域
本发明涉及生物干细胞技术领域,尤其是涉及一种改善肝功能障碍的干细胞制剂。
背景技术
肝是人体五脏之一,是脊椎动物身体内以代谢功能为主的一个器官,并在身体里面充分扮演着去氧化、储存肝糖、分泌性蛋白质的合成等等。
肝功能障碍是指机体的肝细胞变性、坏死,导致肝细胞内的蛋白下降引起的肝功能障碍。肝功能障碍包括各种急、慢性肝脏疾病引起的肝功能异常,如肝硬化、肝衰竭及肝癌病人,同时也包括危重症病人、严重感染、手术、创伤所继发的肝功能障碍。肝硬化是在慢性肝损伤基础上形成的肝纤维化及再生结节形成,最终将导致肝功能衰竭和门脉高压,进展至疾病的终末期。肝衰竭慢加急肝衰竭和慢性肝衰竭,慢加急肝衰竭是在慢性肝病基础上发生的急性肝功能衰竭,慢性肝衰竭则是肝硬化终末期的一种表现。
肝衰竭、肝硬化都是起始于肝纤维化,各种病因引起肝细胞发生炎症及坏死等变化,进而刺激肝脏中胶原蛋白等细胞外基质的合成与降解平衡失调,导致肝内纤维结缔组织异常沉积,最终导致肝纤维化。若肝纤维化持续发展,使肝小叶结构改建、假小叶及结节形成,则成为肝硬化。
近年来,随着干细胞的分离、培养技术不断发展,为多种肝病的临床干预提供了新的思路。干细胞疗法在脂肪肝转化为肝硬化中起到重要的作用,能够帮助改善患者的预后以及生活质量,从而有效提高其预期寿命。
近期研究也表明,间充质干细胞外泌体对多种器官损伤模型的再生起到的作用,与间充质干细胞所起的作用一致,并且越来越多的研究数据强度了这类外泌体在肝脏疾病的修复和再生中的潜力。间充质干细胞外泌体在肝脏疾病动物模型的治疗中表现出了积极的效果,包括急性药物性肝损伤、肝纤维化和肝细胞癌。
另外,活性氧自由基引发的氧化应激是多种肝病发病的共同病理生理基础。氧化应激主要通过启动膜脂质过氧化改变生物膜功能、与生物大分子共价结合及破坏酶的活性等在细胞因子的共同作用下引起不同程度的肝损伤。氧化应激在脂肪肝、病毒性肝炎、肝纤维化等肝病中可产生不容忽视的作用。
因此,如何利用干细胞外泌体提供一种能够有效改善肝功能障碍的制剂成为现有技术中亟待解决的问题。
发明内容
有鉴于此,本发明旨在提出一种改善肝功能障碍的干细胞制剂。
为达到上述目的,本发明的技术方案是这样实现的:
一种改善肝功能障碍的干细胞制剂,由脐带间充质干细胞外泌体、芍药提取物以及药学上可接受的辅料组成,其中,所述芍药提取物包括根部水提物、根部醇提物和根部乙酸乙酯提取物,且3者的重量份数比为(3-5):(1-2):(1-2)。
间充质干细胞(mesenchymal stem cells,MSCs)是一类来源于发育早期中胚层的多能干细胞,是目前研究最多、最重要的成体干细胞之一。由于脐带间充质干细胞具备采集方便、增殖能力强和免疫原性低的优势,其分泌的外泌体常被用于再生医学和各种疾病的治疗研究。包括肾病、老年性痴呆、糖尿病、脊髓损伤、肝病、心脏病、创伤愈合等多种疾病。在脐带来源MSC-EXO的研究报道中,MSCs的所有优点均保留了下来,包括从脐带MSCs分泌的低免疫原性治疗因子、强大的组织修复和免疫调节作用。在具有相同功能的同时,脐带MSC-EXO还拥有更显著的安全性。脐带MSC-EXO对肾脏和肝脏没有不良影响,还有研究证明,脐带MSC-EXO可以促进细胞增殖和保护细胞免受过氧化氢诱导的凋亡。
脐带MSC-EXO注射剂治疗急性和慢性肝损伤和四氯化碳诱导的肝肿瘤,抑制了急性肝损伤、肝纤维化以及肝肿瘤的生长,随后在体内和体外抑制了细胞凋亡和氧化应激。脐带MSC-EXO和不同的抗氧化剂具有保肝作用。而且,脐带MSC-EXO在抑制四氯化碳诱导的肝损伤和肿瘤发展中有很强的抗氧化活性。另一方面,在急性肝衰竭模型中,在体外和体内使用脐带MSC-EXO可降低NLRP3炎性体表达、炎性因子以及ALT和AST水平。
苟药作为一种具有较高的药用价值的传统中药,包含多种生物活性物质,包括蔽类化合物、黄酮类化合物、留体类化合物、苷类化合物、酌类化合物、鞋质类化合物以及挥发油等。其中,芍药根作为一种传统中药具有很长的历史,具有抗炎、镇痛、抗菌、抗氧化、抗癌、抗抑郁、抗肝脏纤维化等作用。有研究发现,芍药乙酸乙酯萃取物和乙醚萃取物表现出很强的总抗氧化能力和1,1-二苯基-2-三硝基苯肼自由基清除能力,并且对羟自由基引起的牛血清白蛋白氧化损伤具有保护作用。芍药总苷通过降低谷草转氨酶、乳酸脱氢酶和肌酸激酶的活性,增加超氧化物歧化酶活性,降低丙二醛水平,对异丙肾上腺素诱导的大鼠心肌缺血发挥保护作用,这种保护作用可能是通过减轻氧化应激实现的。
进一步,所述脐带间充质干细胞外泌体以蛋白质质量计的重量百分比用量为0.03-0.08%,所述芍药提取物的重量百分比用量为2-4%。
进一步,所述脐带间充质干细胞外泌体以蛋白质质量计的重量百分比用量为0.07%,所述芍药提取物的重量百分比用量为3.4%。
进一步,所述根部水提物、根部醇提物和根部乙酸乙酯提取物的重量份数比为4:1:2。
进一步,所述芍药提取物的原料采用新鲜芍药根或新鲜芍药根细胞培养物。
进一步,所述根部水提物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物浸在50-80℃水中动态提取至少两次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部水提物。
进一步,所述根部醇提物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物用浓度为50-70%乙醇回流提取3次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部醇提物。
进一步,所述根部乙酸乙酯提取物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物用乙酸乙酯回流提取3次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部乙酸乙酯提取物。
本发明还提供了一种改善肝功能障碍的干细胞制剂的制备方法,包括如下步骤:
1)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的50-80℃纯水,动态提取至少两次,每次提取1-2h,同时提取过程中用200-300W超声预处理;最后将浸提产物经离心或抽滤后得根部水提物;
2)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的浓度为50-70%乙醇,在25-30℃的条件下回流提取3次,每次提取1-2h,同时提取过程中用200-300 W超声预处理;最后将浸提产物经离心或抽滤后得根部醇提物;
3)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的乙酸乙酯,在25-30℃的条件下回流提取3次,每次提取1-2h,同时提取过程中用200-300W超声预处理;最后将浸提产物经离心或抽滤后得根部乙酸乙酯提取物;
4)按比例将根部水提物、根部醇提物和根部乙酸乙酯提取物混合均匀,得到芍药提取物;
5)称取配方量的脐带间充质干细胞外泌体,与芍药提取物按比例混合;
6)在混合物的基础添加适量药学上可接受的辅料制剂成型即可。
在本发明中,术语“药学上可接受的辅料”包括药学上可接受的载体、赋形剂、稀释剂等,它们与药物活性成分相容。运用药学上可接受的辅料制备药物制剂对本领域普通技术人员来说是公知的。
本发明的干细胞制剂包含本发明脐带间充质干细胞外泌体和芍药提取物组合物作为活性成分,将该组合物和药学上可接受的辅剂 (如本领域普通技术人员所熟知的载体、赋形剂、稀释剂等)组合在一起,配制成各种制剂,优选为固体制剂和液体制剂,如片剂、丸剂、胶囊、粉剂、混悬剂、颗粒剂、糖浆剂、乳液剂、悬浮液等剂型以及各种缓释剂型。
在本发明的具体实施方式中,新鲜芍药根或新鲜芍药根细胞培养物是等效的,可以相互替换。
在本发明的具体实施方式中,超声提条件可根据超声效果在本发明给出的范围内进行调整。
相对于现有技术,本发明所述的改善肝功能障碍的干细胞制剂具有以下优势:
本发明所述的改善肝功能障碍的干细胞制剂,采用特定浓度范围的干细胞外泌体和芍药提取物配合使用,在对肝损伤动物模型的治疗中表现出了更好的改善效果;同时,芍药提取物采用特定比例的根部水提物、根部醇提物和根部乙酸乙酯提取物能有效提高肝功能的改善效果。而当干细胞外泌体和芍药提取物的浓度超过该范围,其使用效果也会明显下降。
具体实施方式
需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。
下面将结合实施例来详细说明本发明。
1、制备根部水提物
分别取1000g新鲜洗净沥干的赤芍的鲜芍药根和晒干后的干芍药根,分别切成0.1cm厚的薄片;之后分别浸在15000ml(料液比为 1:15)的70℃纯水中动态提取3次,每次提取1.5h,同时提取过程中用300W超声处理;每提取一次便浓缩一次,合并3次的浓缩液,浓缩液10000g离心15min取上清液,上清液经减压浓缩后冻干,即得鲜芍药根的根部水提物A1和干芍药根的根部水提物A2。
2、制备根部醇提物
分别取1000g新鲜洗净沥干的赤芍的鲜芍药根和晒干后的干芍药根,分别切成0.1cm厚的薄片;之后分别浸在15000ml(料液比为 1:15)的浓度为65%乙醇溶液中回流提取3次,每次提取1.5h,同时提取过程中用300W超声处理;每提取一次便浓缩一次,合并3次的浓缩液,浓缩液10000g离心15min取上清液,上清液经减压浓缩后冻干,即得鲜芍药根的根部醇提物B1和干芍药根的根部醇提物B2。
3、制备根部乙酸乙酯提取物
分别取1000g新鲜洗净沥干的赤芍的鲜芍药根和晒干后的干芍药根,分别切成0.1cm厚的薄片;之后分别浸在15000ml(料液比为 1:15)的乙酸乙酯中回流提取3次,每次提取1.5h,同时提取过程中用300W超声处理;每提取一次便浓缩一次,合并3次的浓缩液,浓缩液10000g离心15min取上清液,上清液经减压浓缩后冻干,即得鲜芍药根的根部乙酸乙酯提取物C1和干芍药根的根部乙酸乙酯提取物C2。
4、制备干细胞制剂
脐带间充质干细胞外泌体购自辽宁润基生物科技有限公司生产的脐带间充质干细胞外泌体粉末化。
表1实施例1-10的制剂成分表
干细胞外泌体/g | 芍药提取物/g | 生理盐水/ml | |
实施例1 | 0.03 | 2.0,A1:B1:C1(重量比)=3:1:1 | 97.97 |
实施例2 | 0.05 | 3.0,A1:B1:C1(重量比)=3:2:1 | 96.95 |
实施例3 | 0.07 | 3.4,A1:B1:C1(重量比)=4:1:2 | 96.53 |
实施例4 | 0.08 | 4.0,A1:B1:C1(重量比)=5:1:2 | 95.92 |
实施例5 | 0.07 | 3.4,A1:B1:C1(重量比)=3:2:1 | 96.53 |
实施例6 | 0.07 | 3.4,A1:B1:C1(重量比)=5:1:2 | 96.53 |
实施例7 | 0.07 | 3.0,A1:B1:C1(重量比)=4:1:2 | 96.93 |
实施例8 | 0.07 | 4.0,A1:B1:C1(重量比)=4:1:2 | 95.93 |
实施例9 | 0.05 | 3.4,A1:B1:C1(重量比)=4:1:2 | 96.55 |
实施例10 | 0.08 | 3.4,A1:B1:C1(重量比)=4:1:2 | 96.52 |
表2对比例1-15的制剂成分表
按照上表将干细胞外泌体和芍药提取物溶于生理盐水中制得干细胞制剂。
5、药理实验--慢性肝损伤小鼠模型
造模方法如下:利用10%(体积浓度)四氯化碳(CCl4,溶剂为橄榄油)对八周龄的ICR小鼠(体重约25g)诱导化学肝损伤,腹腔注射,剂量为1ml CCl4/kg体重,每周2次,连续注射4周,建立肝纤维化模型,注射后的小鼠在无菌环境下正常饲养。
选取造模成功的实验动物随机分成26个组,每组6只,随机选取其中10组作为1-10号实验组,每天分别腹腔注射5ml实施例1-10 制备的干细胞制剂;从剩余的小组中随机选取15组作为11-25号实验组,每天分别腹腔注射5ml对比例1-15制备的干细胞制剂,剩余一组作为对照组,每天腹腔注射5ml的生理盐水。制剂和盐水每天注射一次,连续注射2周。
另外,选取5只同批次的八周龄的ICR小鼠,这5只小鼠不做任何处理,作为正常组,同造模小鼠一同正常饲养。
最后一次注射结束后,饲养至第28天。
5.1血清转氨酶水平检测
乙醚麻醉后下腹腔主动脉取血,离心制备血清,用于检测谷丙转氨酶(ALT)、谷草转氨酶(AST)。检测结果如表3。
表3血清检测理化参数表
肝功能检查的目的在于探测肝脏有无疾病、肝脏损害程度以及查明肝病原因、判断预后和鉴别发生黄疸的病因等。以血清酶检测常用,包括丙氨酸氨基转移酶(又称谷丙转氨酶,ALT)、门冬氨酸氨基转移酶(又称谷草转氨酶,AST)等。在各种酶试验中,ALT和AST能敏感地反映肝细胞损伤与否及损伤程度。各种急性病毒性肝炎、药物或酒精引起急性肝细胞损伤时,血清ALT最敏感,在临床症状如黄疸出现之前ALT就急剧升高,同时AST也升高,但是AST升高程度不如 ALT。而在慢性肝炎和肝硬化时,AST升高程度超过ALT,因此AST主要反映的是肝脏损伤程度。
通过对比实验组1-10、对照组和正常组可以发现,采用本发明配方配制的干细胞制剂可以明显降低ALT和AST,持续使用可能会越来越接近正常小鼠指标,说明该配方能够有效改善肝功能问题。而且在实验组1-10中,实验组3的效果是最好的,即脐带间充质干细胞外泌体用量为0.07%,芍药提取物用量为3.4%,且根部水提物、根部醇提物和根部乙酸乙酯提取物的重量份数比为4:1:2时效果是最好的,这一结论可以通过实验组3与实验组5-10相比得到。
实验组3与实验组11-14相比可以发现,采用新鲜芍药根制备的提取物效果比干芍药根的效果更好。通过比较实验组3和实验组 15-17可以得出,只有同时使用根部水提物、根部醇提物和根部乙酸乙酯提取物才能达到更优的效果,可能是由于不同的提取溶剂提取出的有效成分有差异,而三种提取物混合可以起到相互弥补、相互协同的效果,从而增强了使用效果。通过比较实验组3和实验组18-19,可以发现只使用干细胞外泌体和芍药提取物的其中一种时,其效果会大打折扣,不如二者同时使用的效果更好,可能是干细胞外泌体具有一定的抗氧化作用,而芍药提取物也具有抗氧化的功效,二者同时增强了整体抗氧化能力,抑制氧化应激反应,从而起到了保护肝脏的作用。另外,芍药提取物中含有苷类化合物,也是治疗急、慢性肝炎、肝硬化的方剂中的重要组方,芍药苷可刺激机体产生血浆纤维联接蛋白,促使其血中水平升高。有研究表明,芍药苷连续使用可明显对抗 D-半乳糖胺或四氯化碳所致小鼠肝损伤后血清谷丙转氨酶升高、血清白蛋白的下降及肝糖原含量下降,并使形态学上肝细胞变性和坏死得到明显的改善和恢复。因此,将干细胞外泌体和芍药提取物联合使用便可以达到更好的改善效果。而通过实验组20-25可以发现,当干细胞外泌体和芍药提取物的使用范围超过本申请所规定的范围时,其使用效果会明显下降,说明在特定范围内的干细胞外泌体和芍药提取物配合使用才会起到更好的改善效果。
5.2肝匀浆的制备及丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH)的测定
取血后,将麻醉的小鼠处死,处死小鼠后,立即取出肝脏,称取 50mg肝组织,用预冷的生理盐水洗去浮血,用生理盐水磨成10%的肝匀浆,检测肝组织匀浆中的MDA、SOD、GSH水平。
表4肝组织匀浆中的MDA、SOD、GSH水平
生物体内,自由基作用于脂质发生过氧化反应,氧化终产物为丙二醛,会引起蛋白质、核酸等生命大分子的交联聚合,且具有细胞毒性。MDA是膜脂过氧化最重要的产物之一,它的产生还能加剧膜的损伤,可通过MDA了解膜脂过氧化的程度,以间接测定膜系统受损程度。
超氧化物歧化酶(Superoxide Dismutase,SOD)是生物体内存在的一种抗氧化金属酶,它能够催化超氧阴离子自由基歧化生成氧和过氧化氢,在机体氧化与抗氧化平衡中起到至关重要的作用,与很多疾病的发生、发展密不可分。
谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-Px)是机体内广泛存在的一种重要的过氧化物分解酶。GSH-Px的活性中心是硒半胱氨酸,其活力大小可以反映机体硒水平。硒是GSH-Px酶系的组成成分,它能催化GSH变为GSSG,使有毒的过氧化物还原成无毒的羟基化合物,从而保护细胞膜的结构及功能不受过氧化物的干扰及损害。
采用CCl4诱导肝纤维化模型时,可在肝内代谢生成三氯甲基自由基,诱发脂质过氧化反应,产生过氧化物,攻击脂质和蛋白质,损伤肝功能,这也模拟了机体内的氧化应激反应。肝匀浆中的MDA的含量可反应肝脏内脂质过氧化的程度,GSH能够反应酶的活性,两者都可以间接反应肝细胞被损伤的程度,SOD是肝脏中的还原性酶,能够清楚损伤肝细胞的氧自由基,监测它的水平可以间接反映机体清楚自由基的能力。
通过对比实验组1-10、对照组和正常组可以发现,采用本发明配方配制的干细胞制剂可以明显降低MDA,同时使GSH和SOD明显升高,说明该配方能够修复损伤的肝细胞,同时提高肝脏中的SOD,从而改善肝功能。而且在实验组1-10中,实验组3的效果是最好的。
通过实验组11-25也可以证明:1、新鲜芍药根制备的提取物效果比干芍药根的效果更好;2、同时使用根部水提物、根部醇提物和根部乙酸乙酯提取物才能达到更优的效果;3、干细胞外泌体和芍药提取物联合使用便可以达到更好的改善效果;4、在特定范围内的干细胞外泌体和芍药提取物配合使用才会起到更好的改善效果。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种改善肝功能障碍的干细胞制剂,其特征在于:由脐带间充质干细胞外泌体、芍药提取物以及药学上可接受的辅料组成,其中,所述芍药提取物包括根部水提物、根部醇提物和根部乙酸乙酯提取物,且3者的重量份数比为(3-5):(1-2):(1-2)。
2.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述脐带间充质干细胞外泌体以蛋白质质量计的重量百分比用量为0.03-0.08%,所述芍药提取物的重量百分比用量为2-4%。
3.根据权利要求2所述的改善肝功能障碍的干细胞制剂,其特征在于:所述脐带间充质干细胞外泌体以蛋白质质量计的重量百分比用量为0.07%,所述芍药提取物的重量百分比用量为3.4%。
4.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述根部水提物、根部醇提物和根部乙酸乙酯提取物的重量份数比为4:1:2。
5.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述芍药提取物的原料采用新鲜芍药根或新鲜芍药根细胞培养物。
6.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述根部水提物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物浸在50-80℃水中动态提取至少两次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部水提物。
7.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述根部醇提物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物用浓度为50-70%乙醇回流提取3次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部醇提物。
8.根据权利要求1所述的改善肝功能障碍的干细胞制剂,其特征在于:所述根部乙酸乙酯提取物由以下步骤制备得到:
将切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物用乙酸乙酯回流提取3次,每次提取1-2h,同时提取过程中用超声处理;最后将浸提产物经离心或抽滤后得根部乙酸乙酯提取物。
9.一种改善肝功能障碍的干细胞制剂的制备方法,其特征在于:包括如下步骤:
1)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的50-80℃纯水,动态提取至少两次,每次提取1-2h,同时提取过程中用200-300W超声预处理;最后将浸提产物经离心或抽滤后得根部水提物;
2)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的浓度为50-70%乙醇,在25-30℃的条件下回流提取3次,每次提取1-2h,同时提取过程中用200-300W超声预处理;最后将浸提产物经离心或抽滤后得根部醇提物;
3)向1份质量的切成0.05-0.3cm厚的新鲜芍药根薄片或新鲜芍药根细胞培养物中加入15-20倍体积的乙酸乙酯,在25-30℃的条件下回流提取3次,每次提取1-2h,同时提取过程中用200-300W超声预处理;最后将浸提产物经离心或抽滤后得根部乙酸乙酯提取物;
4)按比例将根部水提物、根部醇提物和根部乙酸乙酯提取物混合均匀,得到芍药提取物;
5)称取配方量的脐带间充质干细胞外泌体,与芍药提取物按比例混合;
6)在混合物的基础添加适量药学上可接受的辅料制剂成型即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110510202.0A CN113304173A (zh) | 2021-05-11 | 2021-05-11 | 一种改善肝功能障碍的干细胞制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110510202.0A CN113304173A (zh) | 2021-05-11 | 2021-05-11 | 一种改善肝功能障碍的干细胞制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113304173A true CN113304173A (zh) | 2021-08-27 |
Family
ID=77372947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110510202.0A Pending CN113304173A (zh) | 2021-05-11 | 2021-05-11 | 一种改善肝功能障碍的干细胞制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113304173A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062128A (zh) * | 2007-06-18 | 2007-10-31 | 石任兵 | 芍药总苷提取物及其制备方法 |
US20090124007A1 (en) * | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
CN102784366A (zh) * | 2012-09-03 | 2012-11-21 | 赵全成 | 一种具有醒酒保肝作用的药物组合物 |
CN103861088A (zh) * | 2014-03-04 | 2014-06-18 | 奥思达干细胞有限公司 | 一种治疗原发性肝癌的干细胞制剂及其制备方法 |
CN105535022A (zh) * | 2016-01-12 | 2016-05-04 | 浙江生创精准医疗科技有限公司 | 外泌体在制备治疗急性肝衰竭的药物中的用途和药物组合物 |
CN109170305A (zh) * | 2018-08-03 | 2019-01-11 | 深圳市红瑞生物科技有限公司 | 改善宠物肝功能的处方膏及其制备方法 |
-
2021
- 2021-05-11 CN CN202110510202.0A patent/CN113304173A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090124007A1 (en) * | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
CN101062128A (zh) * | 2007-06-18 | 2007-10-31 | 石任兵 | 芍药总苷提取物及其制备方法 |
CN102784366A (zh) * | 2012-09-03 | 2012-11-21 | 赵全成 | 一种具有醒酒保肝作用的药物组合物 |
CN103861088A (zh) * | 2014-03-04 | 2014-06-18 | 奥思达干细胞有限公司 | 一种治疗原发性肝癌的干细胞制剂及其制备方法 |
CN105535022A (zh) * | 2016-01-12 | 2016-05-04 | 浙江生创精准医疗科技有限公司 | 外泌体在制备治疗急性肝衰竭的药物中的用途和药物组合物 |
CN109170305A (zh) * | 2018-08-03 | 2019-01-11 | 深圳市红瑞生物科技有限公司 | 改善宠物肝功能的处方膏及其制备方法 |
Non-Patent Citations (2)
Title |
---|
张娟: ""人脐带血间充质干细胞来源的外泌体对小鼠肝纤维化修复作用的研究"", 《中国学位论文全文数据库》 * |
武谦虎: "《常用治疗肝病中药》", 31 January 2014, 中国医药科技出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Evaluation of the antioxidant and hepatoprotective activity of Terminalia catappa | |
Geng et al. | Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases | |
EP1507544A1 (en) | Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng | |
Zhao et al. | Enhanced antitumor and reduced toxicity effect of Schisanreae polysaccharide in 5-Fu treated Heps-bearing mice | |
CN113151389A (zh) | 一种人参糖肽及制备方法和医药用途 | |
WO2021078288A1 (zh) | 活化胰岛素及治疗糖尿病的复合苦瓜肽口服药及制备方法 | |
CN109662983A (zh) | 中亚苦蒿提取物在制备抗肝癌药物中的应用 | |
CN112791137B (zh) | 三种五味子提取物及其制备工艺和应用 | |
CN109078064A (zh) | 一种覆盆子提取物及其制备方法和应用 | |
Wang et al. | Renoprotective effects of shout camphor Medicinal Mushroom (Taiwanofungus camphorates, Basidiomycetes) Mycelia on several media in mice with chronic kidney disease | |
CN113304173A (zh) | 一种改善肝功能障碍的干细胞制剂 | |
TWI334782B (en) | A pharmaceutical mixture for hepatitis treatment and its preparation method | |
CN112007058A (zh) | 木蝴蝶作为抗氧化应激损伤剂的应用 | |
KR100573375B1 (ko) | 으름덩굴 종자 추출물을 포함하는 항암 조성물 및 그의제조방법 | |
KR100529991B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물 | |
CN108542923A (zh) | 一种从黑木耳中提取的黑色素在保肝产品中的应用 | |
CN115501294B (zh) | 一种布拉氏酵母菌发酵怀山药醇提物的制备方法及应用 | |
EP4059509A1 (en) | Agrimonia eupatoria extract preparation method, and composition for improving liver functions or treating liver diseases, containing extract | |
CN114766622B (zh) | 莓茶决明子固体饮料的制备工艺及其在护肝中的应用 | |
CN114469923B (zh) | 双(2-乙基己基)苯-1,2-二羧酸酯在制备肝损伤药物方面的应用 | |
CN113181173B (zh) | 药用组合物及其在制备用于预防和/或治疗肝癌的产品中的应用 | |
CN111297887B (zh) | 一种白云参保肝活性组分的制备方法及用途 | |
CN115887542A (zh) | 玫瑰花乙醇提取物在制备抗肝纤维化药物或保健食品中的用途 | |
JPS607974B2 (ja) | 肝硬変の予防及び治療剤 | |
KR100470976B1 (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 오갈피추출물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210827 |